Список проголосовавших за комментарий " Notable movers of interest: VRTX +23% after co confirms two Phase 3 Studies of the tezacaftor/ivacaftor combination treatment met primary endpoints<p>The following are some of today's most notable movers of interest, categorized by market capitalization (large cap over $10 billion and mid cap between $2-10 billion) and ranked by % change (all stocks over 100K average daily volume).</p><p><strong>Large Cap Gainers</strong></p><ul><li><strong>VRTX</strong> (110.23 +22.93%): Confirms two Phase 3 Studies of the tezacaftor/ivacaftor combination treatment met primary endpoints with statistically significant improvements in lung function in people with cystic fibrosis.</li><li><strong>REGN</strong> (392.48 +2.6%): Target raised to $446 from $435 at UBS raising Dupixent estimates on pricing details.</li><li><strong>MS</strong> (42.77 +0.66%): Upgraded to Buy from Hold at Deutsche Bank.</li></ul><p><strong>Large Cap Losers</strong></p><ul><li><strong>SNAP</strong> (21.81 -1.8%): Shares continue lower on yesterdays news that Facebook (<strong>FB</strong>) is launching competing 'camera effects' and 'stories'.</li><li><strong>FLT</strong> (153 -2.86%): Shares lower after Capitol Forum reiterated cautious stance. </li></ul><p><strong>Mid Cap Gainers</strong></p><ul><li><strong>VRNT</strong> (42.94 +8.56%): Shares rise on Q4 EPS beat.</li><li><strong>EGO</strong> (3.42 +8.23%): Upgraded to Buy from Hold at Canaccord Genuity.</li><li><strong>EXAS</strong> (23.72 +4.26%): Initiated with a Buy at BofA/Merrill; tgt $29.</li></ul><p><strong>Mid Cap Losers</strong></p><ul><li><strong>PLAY</strong> (59.98 -3.55%): Shares down despite Q4 EPS beat, revs in-line; guides FY18 revs in-line.</li><li><strong>SKX</strong> (29.07 -2.97%): Downgraded to Negative from Positive at Susquehanna.</li><li><strong>DNKN</strong> (54.78 -2.36%): Downgraded to Sell from Neutral at Goldman.</li></ul>"